# Chemed Corp: Form 10-Q for the period ended Jun 30, 2011

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2011-08-05
- Accepted by EDGAR: Aug 5, 2011, 15:57 ET
- Period: 2011-06-30
- Accession: 0001157523-11-004778
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000115752311004778/a6804278.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000115752311004778/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-04-01 to 2011-06-30 | $333.4m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2011-01-01 to 2011-06-30 | $664.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2011-04-01 to 2011-06-30 | $239.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2011-01-01 to 2011-06-30 | $477.1m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2011-04-01 to 2011-06-30 | $50.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2011-01-01 to 2011-06-30 | $106.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-04-01 to 2011-06-30 | $35.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2011-01-01 to 2011-06-30 | $66.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-04-01 to 2011-06-30 | $3.5m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2011-01-01 to 2011-06-30 | $6.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-04-01 to 2011-06-30 | $12.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2011-01-01 to 2011-06-30 | $24.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-04-01 to 2011-06-30 | $20.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2011-01-01 to 2011-06-30 | $38.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-04-01 to 2011-06-30 | $0.94 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2011-01-01 to 2011-06-30 | $1.78 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-04-01 to 2011-06-30 | $0.96 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2011-01-01 to 2011-06-30 | $1.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-04-01 to 2011-06-30 | 21,637,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2011-01-01 to 2011-06-30 | 21,586,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2011-01-01 to 2011-06-30 | $51.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2011-01-01 to 2011-06-30 | $15.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2011-01-01 to 2011-06-30 | $6.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2011-01-01 to 2011-06-30 | $25.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2011-06-30 | $50.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-06-30 | $203.6m | us-gaap:AssetsCurrent |
| Total assets | at 2011-06-30 | $850.6m | us-gaap:Assets |
| Current liabilities | at 2011-06-30 | $135.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-06-30 | $361.3m | us-gaap:Liabilities |
| Long-term debt | at 2011-06-30 | $162.9m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2011-06-30 | $489.3m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2011-06-30 | 21,405,258 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 40,211 characters.

### Executive Summary

We operate through our two wholly owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results for the three and six months ended June 30, 2011 and 2010 (in thousands except per share amounts):

|  | Three months ended June 30, 2011 | 2010 | Six months ended June 30, 2011 | 2010 |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | **$333,360** | $314,995 | **$664,278** | $623,808 |
| Net income | **$20,286** | $18,855 | **$38,387** | $38,213 |
| Diluted EPS | **$0.94** | $0.82 | **$1.78** | $1.66 |
| Adjusted EBITDA | **$46,657** | $44,886 | **$92,275** | $87,957 |
| Adjusted EBITDA as a % of revenue | **14.0%** | 14.2% | **13.9%** | 14.1% |

EBITDA and Adjusted EBITDA are not measures derived in accordance with GAAP. We use Adjusted EBITDA as a measure of earnings for our LTIP awards. We provide EBITDA and Adjusted EBITDA to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements. Our EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our net income to our EBITDA and Adjusted EBITDA is presented on pages 28 and 29.

For the three months ended June 30, 2011, the increase in consolidated service revenues and sales was driven by a 7.3% increase at VITAS and a 2.2% increase at Roto-Rooter. The increase in service revenues at VITAS was a result of increased average daily census (“ADC”) of 5.8%, driven by an increase in admissions of 6.0%, combined with Medicare price increases of approximately 2.1%. Roto-Rooter was driven by a 1.5% price and mix shift increase and a 0.04% increase in job count. When excluding the impact of changes in the number of Company-owned branches, unit-for-unit job count at Roto-Rooter decreased 1.6% during the quarter. The remaining Roto-Rooter revenue increase is related mainly to our independent contractor operations. Consolidated net income increased 7.6% driven mainly by the increase in revenue. Diluted EPS increased 14.6% as a result of the increase in net income and a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue was virtually flat when compared with the prior year. See page 30 for additional VITAS operating metrics.

For the six months ended June 30, 2011, the increase in consolidated service revenues and sales was driven by a 6.5% increase at VITAS and a 6.5% increase at Roto-Rooter. The increase in service revenues at VITAS was a result of increased average daily census (“ADC”) of 5.3%, driven by an increase in admissions of 6.2%, combined with Medicare price increases of approximately 2.1%. Roto-Rooter was driven by a 3.4% price and mix shift increase and a 3.0% increase in job count. Consolidated net income was essential flat over prior year. Diluted EPS increased 7.2% as a result of a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue was virtually flat when compared with the prior year.

VITAS expects to achieve full-year 2011 revenue growth, prior to Medicare cap, of 7.5% to 8.5%. Admissions are estimated to increase approximately 6.5% to 7.0%. Adjusted EBITDA margin prior to Medicare cap is estimated to be 15.3% to 15.8%. Roto-Rooter expects full-year 2011 revenue growth of 6.5% to 8.5%. The revenue estimate is a result of increased pricing of 3.0%, a favorable mix shift to higher revenue jobs, with job count growth estimated at 0.0% to 2.0%. Adjusted EBITDA margin for 2011 is estimated to be in the range of 17.0% to 18.0%. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-17-

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2010 to June 30, 2011 include the following:

- A $5.3 million increase in accounts receivable primarily at VITAS, related to timing of receipts from Medicare.
- A $16.4 million decrease in accounts payable related to timing of payments and a reduction in cash overdrafts payable.
- A $3.9 million increase in accrued compensation related to timing of payroll and bonus payments.

Net cash provided by operating activities increased $30.9 million due primarily to the change in accounts receivable offset by the change in accounts payable and other current liabilities. Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $29.5 million in standby letters of credit as of June 30, 2011, for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of June 30, 2011, we have approximately $320.5 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the $150 million expansion feature. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of June 30, 2011 and anticipate remaining in compliance throughout 2011.

On March 1, 2010 Anthony Morangelli and Frank Ercole filed a class action lawsuit in federal district court for the Eastern District of New York seeking unpaid minimum wages and overtime service technician compensation from Roto-Rooter and Chemed. They also seek payment of penalties, interest and plaintiffs’ attorney fees. We contest these allegations. In September 2010, the Court conditionally certified a class of service technicians, excluding those who signed dispute resolution agreements in which they agreed to arbitrate claims arising out of their employment. In June 2011, the Court granted certification of a class of technicians in 14 states on certain claims. We are unable to estimate our potential liability, if any, with respect to this case.

VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White. This case alleges failure to pay overtime and failure to provide meal and rest periods to California admissions nurses, chaplains and sales representatives. The case seeks payment of penalties, interest and Plaintiffs’ attorney fees. VITAS contests these allegations. In December 2009, the trial court denied Plaintiffs’ motion for class certification. In July 2011, the Court of Appeals affirmed denial of class certification on the travel time, meal and rest period claims, and reversed the trial court’s denial on the off-the-clock and sales representation exemption claims. We are unable to estimate our potential liability, if any, with respect to this case.

Regardless of outcome, defense of litigation adversely affects us through defense costs, diversion of our time and related publicity.

In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice requesting VITAS deliver to the Office of Inspector General (“OIG”) for the Department of Health and Human Services documents, patient records, and policy and procedure manuals for headquarters and its Texas programs concerning hospice services provided for the period January 1, 2003 to the date of the letter. In August 2009, the OIG selected medical records for 59 past and current patients from a Texas program for review. In February 2010, VITAS received a companion civil investigative demand (“CID”) from the State of Texas Attorney General’s Office, seeking related documents. In September 2010, it received a second CID and a second administrative subpoena seeking related documents. In April 2011, the U.S. Attorney provided the Company with a copy of a qui tam complaint filed under seal in U.S. District Court for the Northern District of Texas. In June 2011, the U.S. Attorney provided the company with a partially unsealed second qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas. In June 2011, the U.S. Attorney also provided the Company with a partially unsealed third qui tam complaint filed under seal in the Northern District of Illinois, Eastern Division. The complaint and all the filings in each of these actions remain under seal. The U.S. Attorney has not decided whether to intervene in any of the actions. We are conferring with the U.S. Attorney regarding the Company’s defenses to each complaint’s allegations. We can neither predict the outcome of this investigation nor estimate our potential liability, if any. We believe that we are in compliance with Medicare and Medicaid rules and regulations applicable to hospice providers.

-18-

In April 2005, the OIG served VITAS with civil subpoenas relating to VITAS’ alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS’ three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals affirmed. The government continues to investigate the complaint’s allegations. In March 2009, we received a letter from the government reiterating the basis of their investigation. We are unable to estimate our potential liability, if any, with respect to this matter. We believe that we are in compliance with Medicare and Medicaid rules and regulations applicable to hospice providers.

The costs to comply with either of these investigations were not material for any period presented. Regardless of outcome, responding to the subpoenas can adversely affect us through defense costs, diversion of our time and related publicity.

### Results of Operations

### Three months ended June 30, 2011 versus 2010 - Consolidated Results

Our service revenues and sales for the second quarter of 2011 increased 5.8% versus services and sales revenues for the second quarter of 2010. Of this increase, $16.5 million was attributable to VITAS and $1.9 million was attributable to Roto-Rooter. The following chart shows the components of those changes (dollar amounts in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $13,555 | 8.3 |
| Continuous care | 2,111 | 5.7 |
| General inpatient | 1,194 | 4.6 |
| Medicare cap | (403) | -1151.4 |
| Roto-Rooter |  |  |
| Plumbing | 852 | 2.0 |
| Drain cleaning | 425 | 1.3 |
| Other | 631 | 5.0 |
| Total | $18,365 | 5.8 |

The increase in VITAS’ revenues for the second quarter of 2011 versus the second quarter of 2010 was a result of increased ADC of 5.8% driven by an increase in admissions of 6.0%, combined with Medicare reimbursement rate increases of approximately 2.1%. The ADC increase was driven by a 6.0% increase in routine homecare, an increase of 3.2% in general inpatient and an increase of a 3.1% in continuous care. In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the second quarter of 2011 versus 2010 is attributable to a 2.1% increase in the average price per job and a 0.2% increase in the number of jobs performed. The increase in the plumbing price per job was a result of favorable job mix shift to more expensive jobs such as excavation. Our excavation job count increased by 7.9% compared to 2010. On average, the price per job for our excavation jobs is approximately 5 times greater than the price per job of other plumbing jobs. Drain cleaning revenues for the second quarter of 2011 versus 2010 reflect a 1.2% increase in price per job and a 0.1% increase in the number of jobs performed. The increase in other revenues is attributable to an increase in our independent contractor operations.

The consolidated gross margin was 28.1% in the second quarter of 2011 as compared with 29.0% in the second quarter of 2010. On a segment basis, VITAS’ gross margin was 21.9% in the second quarter of 2011 and 22.7% in the second quarter of 2010. The decrease in VITAS’ gross margin is attributable to a Medicare cap accrual in 2011 versus an Medicare cap reversal in 2010, higher labor costs for admissions and Medicare compliance personnel and the opening of inpatient units which carry significant one time start-up costs as capacity begins to ramp-up. The Roto-Rooter segment’s gross margin was 45.0% for the second quarter of 2011 as compared with 45.2% for the second quarter of 2010.

-19-

Selling, general and administrative expenses (“SG&A”) for the second quarter of 2011 and 2010 comprise (in thousands):

| SG&A expenses before long-term incentive compensation and the impact of market gains and | Three months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| losses of deferred compensation plans | **$49,681** | $48,240 |
| Long-term incentive compensation | **-** | 1,799 |
| Impact of market value gains on liabilities held in |  |  |
| deferred compensation trusts | **743** | (83) |
| Total SG&A expenses | **$50,424** | $49,956 |

Normal salary increases and revenue related expense increases between periods accounts for the 3.0% increase in SG&A expenses before long-term incentive compensation and the impact of market gains of deferred compensation plans.

Depreciation expense increased 2.6% to $6.4 million when compared to the second quarter of 2010 due mainly to the installation of patient software at our VITAS segment during the second quarter of 2010.

Other income for the second quarter of 2011 and 2010 comprise (in thousands):

| Market value gains/(losses) on assets held in deferred | Three months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| compensation trusts | **$743** | $(83) |
| Interest income | **62** | 150 |
| Gain/(loss) on disposal of property and equipment | **32** | (58) |
| Other | **(123)** | 1 |
| Total other income | **$714** | $10 |

Our effective income tax rate decreased to 38.7% in the second quarter of 2011 from 38.9% when compared with the second quarter of 2010.

Net income for both periods included the following after-tax items/adjustments that reduced after-tax earnings (in thousands):

| VITAS | Three months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| Legal expenses of OIG investigation | **$(301)** | $(74) |
| Acquisition expenses | **(31)** | - |
| Roto-Rooter |  |  |
| Expenses of class action litigation | **(113)** | (63) |
| Acquisition expenses | **8** | - |
| Corporate |  |  |
| Stock option expense | **(1,620)** | (1,484) |
| Noncash impact of change in accounting for convertible debt | **(1,155)** | (1,068) |
| Long-term incentive compensation | **-** | (1,124) |
| Total | **$(3,212)** | $(3,813) |

-20-

### Three months ended June 30, 2011 versus 2010 - Segment Results

The change in after-tax earnings for the second quarter of 2011 versus the second quarter of 2010 is due to (dollars in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $308 | 1.7 |
| Roto-Rooter | 232 | 2.6 |
| Corporate | 891 | 10.8 |
|  | $1,431 | 7.6 |

### Six months ended June 30, 2011 versus 2010 - Consolidated Results

Our service revenues and sales for the first six months of 2011 increased 6.5% versus services and sales revenues for the first six months of 2010. Of this increase, $29.2 million was attributable to VITAS and $11.3 million was attributable to Roto-Rooter. The following chart shows the components of those changes (dollar amounts in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $24,981 | 7.8 |
| Continuous care | 3,062 | 4.1 |
| General inpatient | 2,288 | 4.4 |
| Medicare cap | (1,141) | -64.0 |
| Roto-Rooter |  |  |
| Plumbing | 6,979 | 8.6 |
| Drain cleaning | 2,518 | 3.7 |
| Other | 1,783 | 7.2 |
| Total | $40,470 | 6.5 |

The increase in VITAS’ revenues for the first six months of 2011 versus the first six months of 2010 was a result of increased ADC of 5.3% driven by an increase in admissions of 6.2%, combined with Medicare reimbursement rate increases of approximately 2.1%. The ADC increase was driven by a 5.6% increase in routine homecare, an increase of 2.5% in general inpatient and an increase of 1.3% in continuous care. In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first six months of 2011 versus 2010 is attributable to a 5.5% increase in the average price per job and a 3.4% increase in the number of jobs performed. The increase in the plumbing price per job was a result of favorable job mix shift to more expensive jobs such as excavation. Our excavation job count increased by 18.9% compared to 2010. On average, the price per job for our excavation jobs is approximately 5 times greater than the price per job of other plumbing jobs. Drain cleaning revenues for the second quarter of 2011 versus 2010 reflect a 2.9% increase in job count and a 0.9% increase in the average price per job. The increase in other revenues is attributable to an increase in our independent contractor operations and an increase in product sales.

The consolidated gross margin was 28.2% in the first six months of 2011 as compared with 29.0% in the first six months of 2010. On a segment basis, VITAS’ gross margin was 21.8% in the first six months of 2011 and 22.7% in the first six months of 2010. The decrease in VITAS’ gross margin is attributable to a smaller Medicare cap reversal in 2011, higher labor costs for admissions and Medicare compliance personnel and the opening of inpatient units which carry significant one time start-up costs as capacity begins to ramp-up. The Roto-Rooter segment’s gross margin was 44.6% for the first six months of 2011 as compared with 45.2% for the first six months of 2010. The decrease in Roto-Rooter’s gross margin was attributable to continued mix shift to excavation which has higher revenue per job but a slightly lower gross margin percentage per job. An unfavorable adjustment to casualty insurance also contributed to the margin decline.

-21-

Selling, general and administrative expenses (“SG&A”) for the first six months of 2011 and 2010 comprise (in thousands):

| SG&A expenses before long-term incentive compensation and the impact of market gains and | Six months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| losses of deferred compensation plans | **$100,259** | $96,590 |
| Long-term incentive compensation | **3,012** | 1,799 |
| Impact of market value gains on liabilities held in |  |  |
| deferred compensation trusts | **2,807** | 105 |
| Total SG&A expenses | **$106,078** | $98,494 |

Normal salary increases and revenue related expense increases between periods accounts for the 3.8% increase in SG&A expenses before long-term incentive compensation and the impact of market gains of deferred compensation plans.

Depreciation expense increased 8.4% to $12.6 million for the first six months of 2011 due mainly to the installation of patient capture software at our VITAS segment in the second quarter of 2010.

Other income for the second quarter of 2011 and 2010 comprise (in thousands):

| Market value gains on assets held in deferred | Six months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| compensation trusts | **$2,807** | $105 |
| Interest income | **123** | 225 |
| Gain/(loss) on disposal of property and equipment | **11** | (152) |
| Other | **(125)** | 18 |
| Total other income | **$2,816** | $196 |

Our effective income tax rate decreased to 38.6% in the first six months of 2011 from 38.9% when compared with the first six months of 2010.

Net income for both periods included the following after-tax items/adjustments that reduced after-tax earnings (in thousands):

| VITAS | Six months ended June 30, 2011 | 2010 |
| --- | ---: | ---: |
| Legal expenses of OIG investigation | **$(618)** | $(173) |
| Acquisition expenses | **(71)** | - |
| Roto-Rooter |  |  |
| Expenses of class action litigation | **(414)** | (63) |
| Acquisition expenses | **4** | - |
| Corporate |  |  |
| Stock option expense | **(2,843)** | (2,782) |
| Noncash impact of change in accounting for convertible debt | **(2,287)** | (2,115) |
| Long-term incentive compensation | **(1,880)** | (1,124) |
| Total | **$(8,109)** | $(6,257) |

-22-

### Six months ended June 30, 2011 versus 2010 - Segment Results

The change in after-tax earnings for the first six months of 2011 versus the first six months of 2010 is due to (dollars in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $(5) | 0.0 |
| Roto-Rooter | 929 | 5.6 |
| Corporate | (750) | -4.9 |
|  | $174 | 0.5 |

-23-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED JUNE 30, 2011*

*(in thousands)(unaudited)*

| 2011 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $243,095 | $90,265 | $- | $333,360 |
| Cost of services provided and goods sold | 189,940 | 49,657 | - | 239,597 |
| Selling, general and administrative expenses | 19,735 | 24,384 | 6,305 | 50,424 |
| Depreciation | 4,199 | 2,025 | 134 | 6,358 |
| Amortization | 520 | 155 | 464 | 1,139 |
| Total costs and expenses | 214,394 | 76,221 | 6,903 | 297,518 |
| Income/(loss) from operations | 28,701 | 14,044 | (6,903) | 35,842 |
| Interest expense | (62) | (77) | (3,322) | (3,461) |
| Intercompany interest income/(expense) | 1,215 | 652 | (1,867) | - |
| Other income/(expense) - net | (90) | 15 | 789 | 714 |
| Income/(expense) before income taxes | 29,764 | 14,634 | (11,303) | 33,095 |
| Income taxes | (11,175) | (5,542) | 3,908 | (12,809) |
| Net income/(loss) | $18,589 | $9,092 | $(7,395) | $20,286 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,562) | $(2,562) |
| Noncash impact of accounting for convertible debt | - | - | (1,825) | (1,825) |
| Expenses of class action litigation | - | (186) | - | (186) |
| Acquisition expenses | (51) | 12 | - | (39) |
| Legal expenses of OIG investigation | (486) | - | - | (486) |
| Total | $(537) | $(174) | $(4,387) | $(5,098) |
| After-tax benefit/(cost): | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Stock option expense | $- | $- | $(1,620) | $(1,620) |
| Noncash impact of accounting for convertible debt | - | - | (1,155) | (1,155) |
| Expenses of class action litigation | - | (113) | - | (113) |
| Acquisition expenses | (31) | 8 | - | (23) |
| Legal expenses of OIG investigation | (301) | - | - | (301) |
| Total | $(332) | $(105) | $(2,775) | $(3,212) |

-24-

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED JUNE 30, 2010*

*(in thousands)(unaudited)*

| 2010 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $226,638 | $88,357 | $- | $314,995 |
| Cost of services provided and goods sold | 175,257 | 48,445 | - | 223,702 |
| Selling, general and administrative expenses | 18,404 | 24,192 | 7,360 | 49,956 |
| Depreciation | 4,103 | 1,950 | 141 | 6,194 |
| Amortization | 788 | 132 | 367 | 1,287 |
| Total costs and expenses | 198,552 | 74,719 | 7,868 | 281,139 |
| Income/(loss) from operations | 28,086 | 13,638 | (7,868) | 33,856 |
| Interest expense | (48) | (64) | (2,887) | (2,999) |
| Intercompany interest income/(expense) | 1,350 | 773 | (2,123) | - |
| Other income/(expense)—net | 45 | 14 | (49) | 10 |
| Income/(expense) before income taxes | 29,433 | 14,361 | (12,927) | 30,867 |
| Income taxes | (11,152) | (5,501) | 4,641 | (12,012) |
| Net income/(loss) | $18,281 | $8,860 | $(8,286) | $18,855 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,346) | $(2,346) |
| Long-term incentive compensation | - | - | (1,799) | (1,799) |
| Noncash impact of accounting for convertible debt | - | - | (1,688) | (1,688) |
| Expenses of class action litigation | - | (105) | - | (105) |
| Legal expenses of OIG investigation | (118) | - | - | (118) |
| Total | $(118) | $(105) | $(5,833) | $(6,056) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,484) | $(1,484) |
| Long-term incentive compensation | - | - | (1,124) | (1,124) |
| Noncash impact of accounting for convertible debt | - | - | (1,068) | (1,068) |
| Expenses of class action litigation | - | (63) | - | (63) |
| Legal expenses of OIG investigation | (74) | - | - | (74) |
| Total | $(74) | $(63) | $(3,676) | $(3,813) |

-25-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATING STATEMENT OF INCOME FOR THE SIX MONTHS ENDED JUNE 30, 2011 (in thousands)(unaudited)*

| 2011 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $478,768 | $185,510 | $- | $664,278 |
| Cost of services provided and goods sold | 374,241 | 102,814 | - | 477,055 |
| Selling, general and administrative expenses | 38,446 | 51,124 | 16,508 | 106,078 |
| Depreciation | 8,366 | 4,009 | 271 | 12,646 |
| Amortization | 1,003 | 287 | 819 | 2,109 |
| Total costs and expenses | 422,056 | 158,234 | 17,598 | 597,888 |
| Income/(loss) from operations | 56,712 | 27,276 | (17,598) | 66,390 |
| Interest expense | (110) | (142) | (6,453) | (6,705) |
| Intercompany interest income/(expense) | 2,428 | 1,291 | (3,719) | - |
| Other income/(expense)—net | (59) | 5 | 2,870 | 2,816 |
| Income/(expense) before income taxes | 58,971 | 28,430 | (24,900) | 62,501 |
| Income taxes | (22,257) | (10,828) | 8,971 | (24,114) |
| Net income/(loss) | $36,714 | $17,602 | $(15,929) | $38,387 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(4,495) | $(4,495) |
| Long-term incentive compensation | - | - | (3,012) | (3,012) |
| Noncash impact of accounting for convertible debt | - | - | (3,615) | (3,615) |
| Expenses of class action litigation | - | (681) | - | (681) |
| Acquisition expenses | (115) | 6 | - | (109) |
| Legal expenses of OIG investigation | (997) | - | - | (997) |
| Total | $(1,112) | $(675) | $(11,122) | $(12,909) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,843) | $(2,843) |
| Long-term incentive compensation | - | - | (2,287) | (2,287) |
| Noncash impact of accounting for convertible debt | - | - | (1,880) | (1,880) |
| Expenses of class action litigation | - | (414) | - | (414) |
| Acquisition expenses | (71) | 4 | - | (67) |
| Legal expenses of OIG investigation | (618) | - | - | (618) |
| Total | $(689) | $(410) | $(7,010) | $(8,109) |

-26-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATING STATEMENT OF INCOME FOR THE SIX MONTHS ENDED JUNE 30, 2010 (in thousands)(unaudited)*

| 2010 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $449,578 | $174,230 | $- | $623,808 |
| Cost of services provided and goods sold | 347,350 | 95,489 | - | 442,839 |
| Selling, general and administrative expenses | 36,550 | 48,950 | 12,994 | 98,494 |
| Depreciation | 7,587 | 3,901 | 175 | 11,663 |
| Amortization | 1,559 | 255 | 697 | 2,511 |
| Total costs and expenses | 393,046 | 148,595 | 13,866 | 555,507 |
| Income/(loss) from operations | 56,532 | 25,635 | (13,866) | 68,301 |
| Interest expense | (80) | (132) | (5,739) | (5,951) |
| Intercompany interest income/(expense) | 2,639 | 1,475 | (4,114) | - |
| Other income/(expense)—net | 6 | 24 | 166 | 196 |
| Income/(expense) before income taxes | 59,097 | 27,002 | (23,553) | 62,546 |
| Income taxes | (22,378) | (10,329) | 8,374 | (24,333) |
| Net income/(loss) | $36,719 | $16,673 | $(15,179) | $38,213 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(4,397) | $(4,397) |
| Long-term incentive compensation | - | - | (1,799) | (1,799) |
| Noncash impact of accounting for convertible debt | - | - | (3,343) | (3,343) |
| Expenses of class action litigation | - | (105) | - | (105) |
| Legal expenses of OIG investigation | (278) | - | - | (278) |
| Total | $(278) | $(105) | $(9,539) | $(9,922) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,782) | $(2,782) |
| Long-term incentive compensation | - | - | (2,115) | (2,115) |
| Noncash impact of accounting for convertible debt | - | - | (1,124) | (1,124) |
| Expenses of class action litigation | - | (63) | - | (63) |
| Legal expenses of OIG investigation | (173) | - | - | (173) |
| Total | $(173) | $(63) | $(6,021) | $(6,257) |

-27-

*Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended June 30, 2011 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $18,589 | $9,092 | $(7,395) | $20,286 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 62 | 77 | 3,322 | 3,461 |
| Income taxes | 11,175 | 5,542 | (3,908) | 12,809 |
| Depreciation | 4,199 | 2,025 | 134 | 6,358 |
| Amortization | 520 | 155 | 464 | 1,139 |
| **EBITDA** | 34,545 | 16,891 | (7,383) | 44,053 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 486 | - | - | 486 |
| Acquisition expenses | 51 | (12) | - | 39 |
| Expenses of class action litigation | - | 186 | - | 186 |
| Stock option expense | - | - | 2,562 | 2,562 |
| Advertising cost adjustment | - | (607) | - | (607) |
| Interest income | (7) | (9) | (46) | (62) |
| Intercompany interest income/(expense) | (1,215) | (652) | 1,867 | - |
| **Adjusted EBITDA** | $33,860 | $15,797 | $(3,000) | $46,657 |
|  |  |  |  | Chemed |
| For the three months ended June 30, 2010 | VITAS | Roto-Rooter | Corporate | Consolidated |
| **Net income/(loss)** | $18,281 | $8,860 | $(8,286) | $18,855 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 48 | 64 | 2,887 | 2,999 |
| Income taxes | 11,152 | 5,501 | (4,641) | 12,012 |
| Depreciation | 4,103 | 1,950 | 141 | 6,194 |
| Amortization | 788 | 132 | 367 | 1,287 |
| **EBITDA** | 34,372 | 16,507 | (9,532) | 41,347 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 118 | - | - | 118 |
| Long-term incentive compensation | - | - | 1,799 | 1,799 |
| Expenses of class action litigation | - | 105 | - | 105 |
| Stock option expense | - | - | 2,346 | 2,346 |
| Advertising cost adjustment | - | (679) | - | (679) |
| Interest income | (90) | (25) | (35) | (150) |
| Intercompany interest income/(expense) | (1,350) | (773) | 2,123 | - |
| **Adjusted EBITDA** | $33,050 | $15,135 | $(3,299) | $44,886 |

-28-

*Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the six months ended June 30, 2011 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $36,714 | $17,602 | $(15,929) | $38,387 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 110 | 142 | 6,453 | 6,705 |
| Income taxes | 22,257 | 10,828 | (8,971) | 24,114 |
| Depreciation | 8,366 | 4,009 | 271 | 12,646 |
| Amortization | 1,003 | 287 | 819 | 2,109 |
| **EBITDA** | 68,450 | 32,868 | (17,357) | 83,961 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 997 | - | - | 997 |
| Acquisition expenses | 115 | (6) | - | 109 |
| Expenses of class action litigation | - | 681 | - | 681 |
| Long-term incentive compensation | - | - | 3,012 | 3,012 |
| Stock option expense | - | - | 4,495 | 4,495 |
| Advertising cost adjustment | - | (857) | - | (857) |
| Interest income | (44) | (16) | (63) | (123) |
| Intercompany interest income/(expense) | (2,428) | (1,291) | 3,719 | - |
| **Adjusted EBITDA** | $67,090 | $31,379 | $(6,194) | $92,275 |
|  |  |  |  | Chemed |
| For the six months ended June 30, 2010 | VITAS | Roto-Rooter | Corporate | Consolidated |
| **Net income/(loss)** | $36,719 | $16,673 | $(15,179) | $38,213 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 80 | 132 | 5,739 | 5,951 |
| Income taxes | 22,378 | 10,329 | (8,374) | 24,333 |
| Depreciation | 7,587 | 3,901 | 175 | 11,663 |
| Amortization | 1,559 | 255 | 697 | 2,511 |
| **EBITDA** | 68,323 | 31,290 | (16,942) | 82,671 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 278 | - | - | 278 |
| Expenses of class action litigation | - | 105 | - | 105 |
| Long-term incentive compensation | - | - | 1,799 | 1,799 |
| Stock option expense | - | - | 4,397 | 4,397 |
| Advertising cost adjustment | - | (1,068) | - | (1,068) |
| Interest income | (135) | (27) | (63) | (225) |
| Intercompany interest income/(expense) | (2,639) | (1,475) | 4,114 | - |
| **Adjusted EBITDA** | $65,827 | $28,825 | $(6,695) | $87,957 |

-29-

### CHEMED CORPORATION AND SUBSIDIARY COMPANIES OPERATING STATISTICS FOR VITAS SEGMENT (unaudited)

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended June 30, 2011 | 2010 | Six Months Ended June 30, 2011 | 2010 |
| --- | ---: | ---: | ---: | ---: |
| Homecare | **$177,067** | $163,512 | **$345,719** | $320,738 |
| Inpatient | **27,183** | 25,989 | **54,569** | 52,281 |
| Continuous care | **39,213** | 37,102 | **77,838** | 74,776 |
| Total before Medicare cap allowance | **$243,463** | $226,603 | **$478,126** | $447,795 |
| Medicare cap allowance | **(368)** | 35 | **642** | 1,783 |
| Total | **$243,095** | $226,638 | **$478,768** | $449,578 |
| Net revenue as a percent of total |  |  |  |  |
| before Medicare cap allowance |  |  |  |  |
| Homecare | **72.7%** | 72.1% | **72.2%** | 71.6% |
| Inpatient | **11.2** | 11.5 | **11.4** | 11.7 |
| Continuous care | **16.1** | 16.4 | **16.4** | 16.7 |
| Total before Medicare cap allowance | **100.0** | 100.0 | **100.0** | 100.0 |
| Medicare cap allowance | **(0.2)** | - | **0.1** | 0.4 |
| Total | **99.8%** | 100.0% | **100.1%** | 100.4% |
| Average daily census (days) |  |  |  |  |
| Homecare | **9,229** | 8,345 | **9,031** | 8,229 |
| Nursing home | **3,034** | 3,223 | **3,034** | 3,193 |
| Routine homecare | **12,263** | 11,568 | **12,065** | 11,422 |
| Inpatient | **447** | 433 | **449** | 438 |
| Continuous care | **601** | 583 | **602** | 594 |
| Total | **13,311** | 12,584 | **13,116** | 12,454 |
| Total Admissions | **15,294** | 14,423 | **31,092** | 29,267 |
| Total Discharges | **14,885** | 14,132 | **30,419** | 28,685 |
| Average length of stay (days) | **77.1** | 77.4 | **78.0** | 76.6 |
| Median length of stay (days) | **14.0** | 14.0 | **14.0** | 14.0 |
| ADC by major diagnosis |  |  |  |  |
| Neurological | **34.2%** | 32.8% | **34.2%** | 32.8% |
| Cancer | **17.7** | 18.1 | **17.8** | 18.5 |
| Cardio | **11.5** | 12.0 | **11.7** | 11.9 |
| Respiratory | **6.9** | 6.5 | **6.8** | 6.6 |
| Other | **29.7** | 30.6 | **29.5** | 30.2 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |  |  |
| Neurological | **19.4%** | 18.5% | **19.5%** | 18.6% |
| Cancer | **32.8** | 33.8 | **32.2** | 33.8 |
| Cardio | **10.8** | 11.2 | **11.0** | 11.4 |
| Respiratory | **8.5** | 8.5 | **8.8** | 8.5 |
| Other | **28.5** | 28.0 | **28.5** | 27.7 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Direct patient care margins |  |  |  |  |
| Routine homecare | **52.4%** | 52.1% | **51.7%** | 51.6% |
| Inpatient | **13.3** | 12.3 | **13.1** | 13.7 |
| Continuous care | **20.2** | 21.2 | **20.4** | 21.0 |
| Homecare margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$53.23** | $52.52 | **$54.28** | $53.21 |
| Drug costs | **8.21** | 7.67 | **8.08** | 7.72 |
| Home medical equipment | **6.66** | 7.26 | **6.66** | 7.38 |
| Medical supplies | **2.83** | 2.46 | **2.79** | 2.45 |
| Inpatient margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$311.26** | $301.81 | **$308.97** | $294.27 |
| Continuous care margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$550.40** | $530.05 | **$547.29** | $528.23 |
| Bad debt expense as a percent of revenues | **0.8%** | 0.9% | **0.7%** | 0.9% |
| Accounts receivable -- |  |  |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **37.2** | 42.3 | **n.a.** | n.a. |
| Days of revenue outstanding- including unapplied Medicare payments | **36.8** | 34.1 | **n.a.** | n.a. |

-30-

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 291 characters.

Our primary market risk exposure relates to interest rate risk exposure through variable interest rate borrowings. At June 30, 2011, we had no variable rate debt outstanding. At June 30, 2011, the fair value of the Notes approximates $195.6 million which have a face value of $187.0 million.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 141 characters.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

-31-

Filed Aug 5, 2011.
Source: SEC EDGAR, the filing index for accession 0001157523-11-004778. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
